KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Research & Development (2019 - 2025)

Historic Research & Development for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $50.5 million.

  • Royalty Pharma's Research & Development rose 1000000.0% to $50.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $452.0 million, marking a year-over-year increase of 2250000.0%. This contributed to the annual value of $452.0 million for FY2025, which is 2250000.0% up from last year.
  • Latest data reveals that Royalty Pharma reported Research & Development of $50.5 million as of Q4 2025, which was up 1000000.0% from $50.5 million recorded in Q3 2025.
  • Royalty Pharma's 5-year Research & Development high stood at $300.5 million for Q2 2025, and its period low was $500000.0 during Q1 2023.
  • Its 5-year average for Research & Development is $44.2 million, with a median of $14.3 million in 2021.
  • Its Research & Development has fluctuated over the past 5 years, first crashed by 9950.25% in 2023, then skyrocketed by 6000000.0% in 2025.
  • Royalty Pharma's Research & Development (Quarter) stood at $103.8 million in 2021, then tumbled by 51.35% to $50.5 million in 2022, then plummeted by 99.01% to $500000.0 in 2023, then changed by 0.0% to $500000.0 in 2024, then surged by 10000.0% to $50.5 million in 2025.
  • Its Research & Development stands at $50.5 million for Q4 2025, versus $50.5 million for Q3 2025 and $300.5 million for Q2 2025.